Johnson & Johnson announces data from two Darzalex Faspro studies

Johnson & Johnson announced data from two studies highlighting that a Darzalex Faspro based quadruplet regimen demonstrated deep and sustained minimal residual disease negativity rates, and improved long-term progression-free survival in patients with newly diagnosed multiple myeloma, regardless of transplant status. Findings were highlighted as oral presentations of an analysis of sustained MRD in transplant-eligible patients from the Phase 3 PERSEUS study and a subgroup analysis of transplant-ineligible patients in the Phase 3 CEPHEUS study (at the 2025 American Society of Clinical Oncology Annual Meeting. “Across multiple studies, the growing body of data on Darzalex-based regimens indicates impressive, deep responses and meaningful progression-free survival in patients with newly diagnosed multiple myeloma, including high risk. These consistent results across patient populations, regardless of transplant eligibility, reinforce the role of Darzalex Faspro as a cornerstone of frontline therapy,” said Jordan Schecter, MD, Vice President, Disease Area Leader, Multiple Myeloma, Johnson & Johnson Innovative Medicine.